Immunotherapy adaptation in lung cancer during the COVID-19 pandemic
Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION: COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400mg every 6weeks, nivolumab to 480mg every 4weeks. The objective of our study was to assess the impact on quality of life, and on psychological state, as well as the tolerance, of this new schedule.
METHODS: Thoracic oncologic patients who underwent these therapeutic changes in our center during the first COVID-19 epidemic wave were included. Their quality of life was assessed using the Quality of Life Questionnaire-30, their psychological state by the Hospital Anxiety Depression (HAD) scale. We also reported the preferred administration schedule, as well as adverse events.
RESULTS: Thirty patients were included. The overall quality of life was preserved. Rates on HAD scale were low. Tolerance was acceptable. In majority, patients preferred the new procedure. They had a significantly better quality of life compared to those who preferred the old one.
CONCLUSIONS: This new immunotherapy schedule in thoracic oncology is well tolerated and allows a preservation of quality of life. This therapeutic option may be favored in the context of COVID-19 pandemics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 38(2021), 9 vom: 05. Nov., Seite 865-872 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie |
|---|
| Beteiligte Personen: |
Travert, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 17.11.2021 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2021.06.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327923601 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327923601 | ||
| 003 | DE-627 | ||
| 005 | 20231225201848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2021.06.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM327923601 | ||
| 035 | |a (NLM)34246519 | ||
| 035 | |a (PII)S0761-8425(21)00307-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Travert, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy adaptation in lung cancer during the COVID-19 pandemic |
| 246 | 3 | 3 | |a COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.11.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400mg every 6weeks, nivolumab to 480mg every 4weeks. The objective of our study was to assess the impact on quality of life, and on psychological state, as well as the tolerance, of this new schedule | ||
| 520 | |a METHODS: Thoracic oncologic patients who underwent these therapeutic changes in our center during the first COVID-19 epidemic wave were included. Their quality of life was assessed using the Quality of Life Questionnaire-30, their psychological state by the Hospital Anxiety Depression (HAD) scale. We also reported the preferred administration schedule, as well as adverse events | ||
| 520 | |a RESULTS: Thirty patients were included. The overall quality of life was preserved. Rates on HAD scale were low. Tolerance was acceptable. In majority, patients preferred the new procedure. They had a significantly better quality of life compared to those who preferred the old one | ||
| 520 | |a CONCLUSIONS: This new immunotherapy schedule in thoracic oncology is well tolerated and allows a preservation of quality of life. This therapeutic option may be favored in the context of COVID-19 pandemics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Carcinome bronchique non à petites cellules | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Immunothérapie | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Qualité de vie | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV2 | |
| 700 | 1 | |a Cannone, P |e verfasserin |4 aut | |
| 700 | 1 | |a Greillier, L |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasini, P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 38(2021), 9 vom: 05. Nov., Seite 865-872 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2021 |g number:9 |g day:05 |g month:11 |g pages:865-872 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2021.06.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2021 |e 9 |b 05 |c 11 |h 865-872 | ||